Original Article An analysis on clinicopathological features and prognostic factors of patient with primary hepatic lymphoma

* Equal contributors. Received July 1, 2015; Accepted December 24, 2015; Epub January 1, 2016; Published January 15, 2016 Abstract: Objective: To explore the clinicopathological features and prognostic factors of primary hepatic lymphoma. Methods: A retrospective analysis was performed on the clinicopathological features and follow-up data of 105 pa- tients with PHL in our hospital from January 1980 to October 2012. Survival rates were estimated by Kaplan Meier analysis and prognostic factors were analyzed with Cox regression model. Results: The mean age of patients with PHL was (54.3 ± 14.7) years old and the tumor was 4 to 15 cm in long diameter. In the mode of invasion, nodular invasion accounted for 63.8% (67/105) and diffuse invasion accounted for 36.2% (38/105). In pathological type, diffuse large B-cell lymphoma accounted for 57.1% (60/105), peripheral T-cell lymphoma accounted for 34.3% (36/105) and extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue accounted for 8.6% (9/105). The median survival time of the 105 patients with PHL was 28 months (8~120 months), and the survival rates in 1, 3 and 5 years were 69.5%, 42.9% and 26.7% respectively. Univariate analysis showed that the survival rate was statistically significant among patients with differences in age, number and size of tumor, mode of invasion and pathological type (P < 0.05). Cox proportional hazards regression analysis showed that age above 60 years old (HR = 1.92, 95% CI: 1.28~2.89), tumor size ≥ 10 cm (HR = 2.17, 95% CI: 1.32~3.56), diffuse invasion (HR = 1.79, 95% CI: 1.21~2.65) and peripheral T-cell lymphoma (HR = 2.76, 95% CI: 1.65~4.63) were independent risk fac- tors of prognosis for the patients. Conclusion: The main pathological type of PHL is diffuse large B-cell lymphoma. Old age, tumor size ≥ 10 cm, peripheral T-cell lymphoma and diffuse infiltrative tumor cells are the risk factors of prognosis for patients with PHL.